UBI Pharma Inc.

6562

TW0006562002

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 23:00:00 05/05/2024 BST			5-day change	1st Jan Change
14.25 ^TWD	+1.79%		0.00%	-58.87%

04-18	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Securities and Futures Investors Protection Center and Jih Sun Securities Co., Ltd. cancelled the acquisition of 1.36% stake in United BioPharma, Inc. from Jih Sun Financial Holding Co., Ltd..

January 12, 2017

Securities and Futures Investors Protection Center and Jih Sun Securities Co., Ltd. agreed to acquire 1.36% stake in United BioPharma, Inc. (GTSM:6471) from Jih Sun Financial Holding Co., Ltd. (GTSM:5820) for TWD 83.8 million on January 13, 2016. Securities and Futures Investors Protection Center and Jih Sun Securities Co., Ltd. will acquire 1.7 million shares at TWD 50 per share.

Securities and Futures Investors Protection Center and Jih Sun Securities Co., Ltd. cancelled the acquisition of 1.36% stake in United BioPharma, Inc. (GTSM:6471) from Jih Sun Financial Holding Co., Ltd. (GTSM:5820) on January 13, 2017.

Latest news about UBI Pharma Inc.

UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-18	CI
UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	11/08/23	CI
UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	21/04/23	CI
UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	15/08/22	CI
UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	29/04/22	CI
UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	29/04/22	CI
Medigen Vaccine Biologics : Taiwan rejects COVID vaccine candidate, president to get domestic shot	16/08/21	RE
Medigen Vaccine Biologics : Taiwan denies approval for UBI's COVID-19 vaccine candidate	16/08/21	RE
Ubi Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	12/08/21	CI
UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	13/04/21	CI
Ubi Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	11/08/20	CI
Ubi Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	08/04/20	CI
Ubi Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2019	13/08/19	CI
Ubi Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	24/04/19	CI
Securities and Futures Investors Protection Center and Jih Sun Securities Co., Ltd. cancelled the acquisition of 1.36% stake in United BioPharma, Inc. from Jih Sun Financial Holding Co., Ltd..	12/01/17	CI
Securities and Futures Investors Protection Center and Jih Sun Securities Co., Ltd. agreed to acquire 1.36% stake in UBI Pharma Inc. from Jih Sun Financial Holding Co., Ltd. for TWD 83.8 million.	12/01/16	CI

Chart UBI Pharma Inc.

Duration

Period

More charts

Company Profile

UBI Pharma Inc is a Taiwan-based company mainly engaged in development and manufacturing of protein drugs and special dosage-form drugs. The Company is engaged in research and development, manufacturing and sales of protein drugs and special dosage-form drugs, contract manufacturing of pharmaceuticals, and provision of contract research services. The protein drug product line includes erythropoietin (UB-851) biosimilar drugs, innovative long-acting erythropoietin (UB-852), innovative long-acting granular ball community stimulating hormone (UB-853), and others used to treat anemia, neutropenia. The small molecule new drug product line includes B-Raf kinase inhibitor (UB-941) for the treatment of melanoma. The special scientific name drug product line includes tablets Olanzapine and Nevirapin for the treatment of schizophrenia and AIDS, and injections Granisetronl and Meropenen for the treatment of bacterial infections. It sells products in the domestic market and overseas markets.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
UBI PHARMA INC.	-58.87%	51.94M
ELI LILLY AND COMPANY	+31.06%	682B
NOVO NORDISK A/S	+30.35%	586B
JOHNSON & JOHNSON	-3.42%	364B
MERCK & CO., INC.	+18.02%	327B
ABBVIE INC.	+4.27%	285B
ASTRAZENECA PLC	+15.53%	240B
NOVARTIS AG	+10.16%	209B
ROCHE HOLDING AG	-8.14%	203B
AMGEN INC.	+8.12%	165B